Pharmasinthesis

The company is the largest manufacturer of tuberculosis drugs in Russia, and also develops and produces high-quality innovative drugs for the treatment of cancer, HIV, immune system disorders. It was founded in 1997.

History

2025: Obtaining 1 billion rubles for the launch of the first production of medical equipment and products for dialysis in Russia

Industrial Development Fund (FRP) provided a preferential loan to the Russian pharmaceutical group of companies "Farmasintez" in the amount of 1 billion rubles. The funds will be used to create To Kaluga medical equipment production for products , dialysis Zdrav.Expert representatives of the FRP told the portal on February 7, 2025. Total investments in the project will exceed 2 billion rubles. Previously, such products Russia were supplied mainly by foreign companies, including. the American Baxter

𝓲

Фото: "Pharmasinthesis"

"The Supervisory Board of the Industrial Development Fund approved the provision of 1 billion rubles for the opening of the first comprehensive production of medical equipment and consumables for dialysis in Russia. Pharmasintez-Medtech received a preferential loan from the FRP under the flagship program "Development Projects" at a rate of 3% per annum for a period of five years. Total investments in the project will exceed 2 billion rubles. The creation of a new plant is designed to reduce Russia's dependence on foreign suppliers, provide patients with high-quality medical products and effective therapy, "said Roman Petrutsa, director of the FRP.

According to the company's estimates, the Russian market for equipment and consumables for patients with renal failure as of the beginning of February 2025 consists almost entirely of imported products. Until 2022, the needs for this technique and products were mainly met through the supply of the American company Baxter.

It is expected that the opening of the Pharmasintez plant in Kaluga on the territory of the Rosva industrial park will help increase the share of domestic products for a number of products to 80%. The company will direct the funds of the FRP loan to the purchase of technological equipment for the production of project products.

After reaching full capacity, the enterprise plans to annually produce equipment in the amount of more than 1,500 units (devices for carrying out various types of dialysis), 7 million units of consumables for hemodialysis (dialyzers, arteriovenous main line) and about 13 million units of consumables for peritoneal dialysis.

A distinctive feature of the project is its focus on the development of two dialysis segments at the same time - hemodialysis and peritoneal dialysis. The first method is aimed at purifying blood in dialysis centers and intensive care units, the second is the only home dialysis method available in Russia.

"Back in 2023, the country was actually dependent on imports in the direction of the supply of equipment, consumables and infusion solutions for dialysis. After the sudden withdrawal from the Russian market of the American company Baxter, Farmasintez Group of Companies took emergency measures to launch the production and supply of dialysis solutions. Considering that the supply of equipment and consumables from unfriendly countries is unstable, we decided to make Russia completely independent of the supply of foreign equipment and consumables for dialysis, "said Vikram Punia, President of Farmasintez Group of Companies.

According to him, the first stage of the project, which started with investments in the amount of 2 billion rubles, is the beginning of a large-scale import substitution program for medical equipment and dialysis products. The total project budget until 2030 will exceed 20 billion rubles.

It is worth noting that Pharmasintez invests a large amount of money in its own developments, in particular, in the production of home dialysis equipment, which surpasses in many respects the Western analogues that are present on the Russian market. We pay special attention to the functionality and quality of our equipment and consumables. I would like to thank the Ministry of Industry and Trade of the Russian Federation for the promptly adopted decisions to support the Pharmasintez Group of Companies and the Industrial Development Fund for immediate financing, "added the President of the Farmasintez Group of Companies.

2023: Entering the Ecuadorian market

On July 25, 2023, Pharmasintez Group of Companies announced the receipt of seven marketing authorizations in Ecuador for drugs for the treatment of diabetes mellitus, HIV, as well as for the treatment of malignant neoplasms (chemotherapy drugs), which entitle the import and distribution of drugs in the country.

The drugs will be produced at the Pharmasintez-Nord, Pharmasintez-Tyumen sites and the Irkutsk plant of Pharmasintez JSC.

As of July 2023, Pharmasintez Group of Companies has registered more than 100 drugs in the CIS and Latin America.

Not so long ago, the company received marketing authorizations in the Dominican Republic for the supply of three anticancer drugs manufactured by Pharmasintez-Nord. Entering Ecuador was a step for the company to increase its presence in the market of the Latin American region. As of July 2023, active work is also being carried out with other large countries in the region. We see the potential in cooperation with Latin America, first of all, in a fairly large number of friendly countries that are part of it, with which historically constructive relations have developed in the region, - said Nikita Punia, executive director of Farmasintez Group of Companies.

In July 2023, the Pharmasintez-Nord research and production complex, which is part of the Pharmasintez group of companies, successfully passed the inspection of the Syrian Ministry of Health for compliance with GMP standards and received official permission to supply manufactured drugs to the territory of the Syrian Arab Republic.

2022: Pharmasintez invests 1 billion rubles in the production of bronchodilators in Irkutsk

In mid-June 2022, it became known that Farmasintez invested about 1 billion rubles in the production of bronchodilators (drugs that relieve the symptoms of bronchospasm and are used in the treatment bronchial asthma and chronic obstructive disease) lungs in the Irkutsk region. According to the press service of the regional government, within the framework of the project, two sites are planned for the production of hormonal and non-hormonal drugs.

It is expected that the volume of production will be 136 million capsules with powder for inhalation and 867 thousand aerosols for inhalation per year. The receipt of products into circulation is scheduled for the first quarter of 2024.

Pharmasintez invests 1 billion rubles in the production of bronchodilators in Irkutsk

An agreement on socio-economic cooperation is already in force between the government of the Irkutsk region and Farmasintez, and the signed document has become its addition. Under the agreement, Pharmasintez participates in social events in the region, provides charitable assistance to those in need, and also provides material support to Irkutsk State University (ISU), Irkutsk National Research Technical University (IRNIT) and the Institute of Chemistry named after Favorsky Siberian Branch of the Russian Academy of Sciences.

In June 2022, Pharmasintez also announced its intention to launch the production of hormonal drugs at its plant in the Tyumen region. Investments in this project will amount to more than 4 billion rubles. The production line will appear in the summer of 2022.

By mid-June 2022, Pharmasintez is one of the largest manufacturers of socially significant drugs in Russia, as well as a developer of innovative drugs. The company's drugs are presented in the main therapeutic areas, such as tuberculosis, HIV, oncology, diabetes mellitus, hepatitis. The group's portfolio includes more than 170 products. The company's production sites are located in Irkutsk, Ussuriysk, St. Petersburg, Bratsk and Tyumen.^[1]

Notes

Investing 0.5 billion rubles in an intravenous nutrition plant

Pharmasintez invests 0.5 billion rubles in the East Farm intravenous nutrition plant in Ussuriysk. The group announced this on February 16, 2022. Read more here.